These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30929420)

  • 1. Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer.
    Lee T; Christov PP; Shaw S; Tarr JC; Zhao B; Veerasamy N; Jeon KO; Mills JJ; Bian Z; Sensintaffar JL; Arnold AL; Fogarty SA; Perry E; Ramsey HE; Cook RS; Hollingshead M; Davis Millin M; Lee KM; Koss B; Budhraja A; Opferman JT; Kim K; Arteaga CL; Moore WJ; Olejniczak ET; Savona MR; Fesik SW
    J Med Chem; 2019 Apr; 62(8):3971-3988. PubMed ID: 30929420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a Myeloid Cell Leukemia 1 (Mcl-1) Inhibitor That Demonstrates Potent
    Tarr JC; Salovich JM; Aichinger M; Jeon K; Veerasamy N; Sensintaffar JL; Arnhof H; Samwer M; Christov PP; Kim K; Wunberg T; Schweifer N; Trapani F; Arnold A; Martin F; Zhao B; Miriyala N; Sgubin D; Fogarty S; Moore WJ; Stott GM; Olejniczak ET; Engelhardt H; Rudolph D; Lee T; McConnell DB; Fesik SW
    J Med Chem; 2024 Aug; 67(16):14370-14393. PubMed ID: 39102508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a Copper-Based Mcl-1 Inhibitor as an Effective Antitumor Agent.
    Lu X; Liu YC; Orvig C; Liang H; Chen ZF
    J Med Chem; 2020 Sep; 63(17):9154-9167. PubMed ID: 32794745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia.
    Tron AE; Belmonte MA; Adam A; Aquila BM; Boise LH; Chiarparin E; Cidado J; Embrey KJ; Gangl E; Gibbons FD; Gregory GP; Hargreaves D; Hendricks JA; Johannes JW; Johnstone RW; Kazmirski SL; Kettle JG; Lamb ML; Matulis SM; Nooka AK; Packer MJ; Peng B; Rawlins PB; Robbins DW; Schuller AG; Su N; Yang W; Ye Q; Zheng X; Secrist JP; Clark EA; Wilson DM; Fawell SE; Hird AW
    Nat Commun; 2018 Dec; 9(1):5341. PubMed ID: 30559424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.
    Wan Y; Dai N; Tang Z; Fang H
    Eur J Med Chem; 2018 Feb; 146():471-482. PubMed ID: 29407973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors.
    Lee T; Bian Z; Zhao B; Hogdal LJ; Sensintaffar JL; Goodwin CM; Belmar J; Shaw S; Tarr JC; Veerasamy N; Matulis SM; Koss B; Fischer MA; Arnold AL; Camper DV; Browning CF; Rossanese OW; Budhraja A; Opferman J; Boise LH; Savona MR; Letai A; Olejniczak ET; Fesik SW
    FEBS Lett; 2017 Jan; 591(1):240-251. PubMed ID: 27878989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells.
    Doi K; Gowda K; Liu Q; Lin JM; Sung SS; Dower C; Claxton D; Loughran TP; Amin S; Wang HG
    Cancer Biol Ther; 2014; 15(12):1688-99. PubMed ID: 25535900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Small-Molecule Inhibitors of the Antiapoptotic Protein Myeloid Cell Leukaemia-1 (Mcl-1).
    Beekman AM; O'Connell MA; Howell LA
    ChemMedChem; 2016 Apr; 11(8):840-4. PubMed ID: 26616140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of Potent and Selective Tricyclic Indole Diazepinone Myeloid Cell Leukemia-1 Inhibitors Using Structure-Based Design.
    Shaw S; Bian Z; Zhao B; Tarr JC; Veerasamy N; Jeon KO; Belmar J; Arnold AL; Fogarty SA; Perry E; Sensintaffar JL; Camper DV; Rossanese OW; Lee T; Olejniczak ET; Fesik SW
    J Med Chem; 2018 Mar; 61(6):2410-2421. PubMed ID: 29323899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).
    Leverson JD; Zhang H; Chen J; Tahir SK; Phillips DC; Xue J; Nimmer P; Jin S; Smith M; Xiao Y; Kovar P; Tanaka A; Bruncko M; Sheppard GS; Wang L; Gierke S; Kategaya L; Anderson DJ; Wong C; Eastham-Anderson J; Ludlam MJ; Sampath D; Fairbrother WJ; Wertz I; Rosenberg SH; Tse C; Elmore SW; Souers AJ
    Cell Death Dis; 2015 Jan; 6(1):e1590. PubMed ID: 25590800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-Based Optimization of 3-Phenyl-
    Li Y; Fan W; Gong Q; Tian J; Zhou M; Li Q; Uwituze LB; Zhang Z; Hong R; Wang R
    J Med Chem; 2021 Jul; 64(14):10260-10285. PubMed ID: 34228434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mcl-1 as a "barrier" in cancer treatment: Can we target it now?
    Pervushin NV; Senichkin VV; Zhivotovsky B; Kopeina GS
    Int Rev Cell Mol Biol; 2020; 351():23-55. PubMed ID: 32247581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of 3,5-Dimethyl-4-Sulfonyl-1
    Zhu PJ; Yu ZZ; Lv YF; Zhao JL; Tong YY; You QD; Jiang ZY
    J Med Chem; 2021 Aug; 64(15):11330-11353. PubMed ID: 34342996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of Novel Mcl-1 Inhibitors with a 3-Substituted-1
    Deng H; Zhang J; Liu L; Zhang H; Han Y; Wu L; Jing Y; Huang M; Zhao L
    J Med Chem; 2024 Aug; 67(16):13925-13958. PubMed ID: 39121336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and in Vivo Evaluation of Macrocyclic Mcl-1 Inhibitors Featuring an α-Hydroxy Phenylacetic Acid Pharmacophore or Bioisostere.
    Rescourio G; Gonzalez AZ; Jabri S; Belmontes B; Moody G; Whittington D; Huang X; Caenepeel S; Cardozo M; Cheng AC; Chow D; Dou H; Jones A; Kelly RC; Li Y; Lizarzaburu M; Lo MC; Mallari R; Meleza C; Rew Y; Simonovich S; Sun D; Turcotte S; Yan X; Wong SG; Yanez E; Zancanella M; Houze J; Medina JC; Hughes PE; Brown SP
    J Med Chem; 2019 Nov; 62(22):10258-10271. PubMed ID: 31736296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents.
    Bolomsky A; Vogler M; Köse MC; Heckman CA; Ehx G; Ludwig H; Caers J
    J Hematol Oncol; 2020 Dec; 13(1):173. PubMed ID: 33308268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.
    Pan R; Ruvolo VR; Wei J; Konopleva M; Reed JC; Pellecchia M; Andreeff M; Ruvolo PP
    Blood; 2015 Jul; 126(3):363-72. PubMed ID: 26045609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel BH3 α-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak.
    Cao X; Yap JL; Newell-Rogers MK; Peddaboina C; Jiang W; Papaconstantinou HT; Jupitor D; Rai A; Jung KY; Tubin RP; Yu W; Vanommeslaeghe K; Wilder PT; MacKerell AD; Fletcher S; Smythe RW
    Mol Cancer; 2013 May; 12(1):42. PubMed ID: 23680104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interdiction at a protein-protein interface: MCL-1 inhibitors for oncology.
    Li K
    Bioorg Med Chem Lett; 2021 Jan; 32():127717. PubMed ID: 33253879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib.
    Young AI; Law AM; Castillo L; Chong S; Cullen HD; Koehler M; Herzog S; Brummer T; Lee EF; Fairlie WD; Lucas MC; Herrmann D; Allam A; Timpson P; Watkins DN; Millar EK; O'Toole SA; Gallego-Ortega D; Ormandy CJ; Oakes SR
    Breast Cancer Res; 2016 Dec; 18(1):125. PubMed ID: 27931239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.